argenx SE reported $4.3B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AstraZeneca USD 4.89B 2.67B Jun/2026
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Qiagen NV USD 646.29M 192.72M Mar/2026
UCB EUR 1.57B 1.14B Dec/2024